Tandem Investment Advisors Inc. Sells 9,076 Shares of Stryker Corporation $SYK

Tandem Investment Advisors Inc. cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.2% in the 4th quarter, HoldingsChannel reports. The firm owned 271,368 shares of the medical technology company’s stock after selling 9,076 shares during the quarter. Stryker accounts for approximately 3.6% of Tandem Investment Advisors Inc.’s investment portfolio, making the stock its 15th biggest holding. Tandem Investment Advisors Inc.’s holdings in Stryker were worth $95,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. VanderPol Investments L.L.C. increased its holdings in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the last quarter. Lantz Financial LLC grew its position in shares of Stryker by 5.0% during the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after acquiring an additional 29 shares during the period. Stonebridge Capital Advisors LLC raised its holdings in shares of Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares during the period. Tcfg Wealth Management LLC lifted its stake in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp increased its position in Stryker by 1.2% in the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after buying an additional 30 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SYK shares. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Canaccord Genuity Group dropped their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. reduced their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Stryker Price Performance

Shares of Stryker stock opened at $316.39 on Tuesday. The company’s fifty day simple moving average is $324.80 and its two-hundred day simple moving average is $349.43. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The firm has a market cap of $121.29 billion, a PE ratio of 36.62, a price-to-earnings-growth ratio of 1.99 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.